Editor: Tabish Qidwai

Drug Repurposing Against SARS-CoV-2

eBook: US $59 Special Offer (PDF + Printed Copy): US $101
Printed Copy: US $71
Library License: US $236
ISBN: 978-981-5123-20-3 (Print)
ISBN: 978-981-5123-19-7 (Online)
Year of Publication: 2023
DOI: 10.2174/97898151231971230101


Drug repurposing is a cost-effective method of discovering new treatments for diseases than traditional drug development methods. It involves virtual screening of chemical candidates with the aid of computational methods like molecular docking.

Drug Repurposing against SARS-CoV2 focuses on current trends in drug repurposing against the novel coronavirus strains. The book aims to give readers an overview of drug repurposing against COVID-19 and various techniques involved in the process. The book consolidates available information on the pathophysiology, drug targets, and drug repurposing against COVID-19 into a single, convenient resource.

Key features

- An up-to-date compilation of the evidence that supports the drug repurposing for COVID-19.

- How to use repurposing of available drugs for disease therapy.

- Provides an improved understanding of pathophysiology and SARS-CoV2 viral entry pathways.

- Provides references for further reading


Undergraduate and postgraduate students with a medical background, research scholars, and scientists working in the area of infectious diseases.


There are seven chapters in this book entitled " Drug Repurposing against SARS-CoV2." The book focuses on current trends in drug repurposing against SARS-CoV2.

The goal of this book is to give readers an overview of drug repurposing in life-threating diseases, drug repurposing in COVID-19, as well as various techniques involved in drug repurposing. The book aims to target students, research scholars, and physicians interested in the topic. The book's structure is well-organized and updated.

Chapter 1 by Ruchi Chawla discusses repurposing drugs: a new paradigm and hopes for life-threatening diseases.

Anand et al., in Chapter 2, outline the repurposed and adjuvant drugs in COVID-19 patients, as well as challenges and ethical issues related to drug repurposing. Chapter 3 by Neelam et al. presents the repurposed drugs against SARS-CoV-2 replication in COVID-19. In Chapter 4, Awesh Yadav et al., describe the targeting of viral entry pathways through repurposed drugs in SARS-CoV-2 infection.

Repurposed drugs or potential pharmacological agents targeting cytokine release, and induction of coagulation in COVID-19 are discussed in Chapter 5 by Arpita Singh et al. In Chapter 6, Qidwai et al., discuss the High-throughput screening (HTS) method for screening of known drugs. The last chapter by Khan et al., discusses drug repurposing for COVID-19 using computational methods.

I believe this book will be of tremendous interest to students, doctors, researchers, and even patients and their families. Finally, I would like to express my gratitude to all of the contributors to this book, as well as the Bentham Publishing Editorial Board for providing us with this invaluable opportunity.

Tabish Qidwai
Faculty of Biotechnology, IBST
Shri Ramswaroop Memorial University
Lucknow-Deva Road
Barabanki, 225003
U.P. India